BSE Live
Dec 29, 16:01Prev. Close
1269.05
Open Price
1269.05
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 29, 15:55Prev. Close
1269.30
Open Price
1269.30
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1268.60 (35)
| Balance Sheet of Dr Reddys Laboratories (in Rs. Cr.) | Mar 05 | Mar 04 | |
| 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | |||
| SHAREHOLDER'S FUNDS | |||
| Equity Share Capital | 38.26 | 38.26 | |
| Total Share Capital | 38.26 | 38.26 | |
| Reserves and Surplus | 2,035.82 | 2,008.76 | |
| Total Reserves and Surplus | 2,035.82 | 2,008.76 | |
| Total Shareholders Funds | 2,074.08 | 2,047.02 | |
| NON-CURRENT LIABILITIES | |||
| Long Term Borrowings | 10.60 | 11.61 | |
| Deferred Tax Liabilities [Net] | 73.85 | 64.33 | |
| Other Long Term Liabilities | 0.00 | 0.00 | |
| Long Term Provisions | 0.00 | 0.00 | |
| Total Non-Current Liabilities | 84.46 | 75.94 | |
| CURRENT LIABILITIES | |||
| Short Term Borrowings | 262.64 | 46.61 | |
| Trade Payables | 351.37 | 284.09 | |
| Other Current Liabilities | 26.28 | 7.30 | |
| Short Term Provisions | 183.18 | 58.13 | |
| Total Current Liabilities | 823.46 | 396.14 | |
| Total Capital And Liabilities | 2,982.00 | 2,519.09 | |
| ASSETS | |||
| NON-CURRENT ASSETS | |||
| Tangible Assets | 532.19 | 427.75 | |
| Intangible Assets | 30.35 | 30.35 | |
| Capital Work-In-Progress | 60.13 | 105.25 | |
| Other Assets | 0.00 | 0.00 | |
| Fixed Assets | 622.67 | 563.35 | |
| Non-Current Investments | 358.46 | 612.05 | |
| Deferred Tax Assets [Net] | 52.70 | 22.07 | |
| Long Term Loans And Advances | 0.00 | 0.00 | |
| Other Non-Current Assets | 0.00 | 0.00 | |
| Total Non-Current Assets | 1,033.82 | 1,197.47 | |
| CURRENT ASSETS | |||
| Current Investments | 0.00 | 0.00 | |
| Inventories | 303.81 | 258.01 | |
| Trade Receivables | 417.64 | 444.05 | |
| Cash And Cash Equivalents | 891.72 | 408.08 | |
| Short Term Loans And Advances | 326.96 | 198.71 | |
| OtherCurrentAssets | 8.05 | 12.77 | |
| Total Current Assets | 1,948.18 | 1,321.63 | |
| Total Assets | 2,982.00 | 2,519.09 | |
| OTHER ADDITIONAL INFORMATION | |||
| CONTINGENT LIABILITIES, COMMITMENTS | |||
| Contingent Liabilities | 189.19 | 208.33 | |
| CIF VALUE OF IMPORTS | |||
| Raw Materials | 189.94 | 185.13 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | |
| Capital Goods | 38.34 | 33.54 | |
| EXPENDITURE IN FOREIGN EXCHANGE | |||
| Expenditure In Foreign Currency | 195.81 | 163.10 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | |||
| Dividend Remittance In Foreign Currency | -- | 0.38 | |
| EARNINGS IN FOREIGN EXCHANGE | |||
| FOB Value Of Goods | 913.90 | 981.55 | |
| Other Earnings | 5.83 | 3.89 | |
| BONUS DETAILS | |||
| Bonus Equity Share Capital | 17.49 | 17.49 | |
| NON-CURRENT INVESTMENTS | |||
| Non-Current Investments Quoted Market Value | 31.88 | 254.94 | |
| Non-Current Investments Unquoted Book Value | 413.63 | 419.48 | |
| CURRENT INVESTMENTS | |||
| Current Investments Quoted Market Value | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- |
15.12.2025
12.12.2025
25.11.2025
11.11.2025
28.10.2025
Dr Reddys Labs Consolidated September 2025 Net Sales at Rs 8,828.30 crore, up 9.83% Y-o-Y
28.10.2025
Dr Reddys Labs Standalone September 2025 Net Sales at Rs 4,618.60 crore, down 31.03% Y-o-Y
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
24.07.2025
Dr Reddys Labs Standalone June 2025 Net Sales at Rs 7,809.50 crore, up 33.7% Y-o-Y
22.01.2025
Dr Reddy's Labs Q3 Preview: Lower Revlimid contribution, subdued US sales to dent earnings growth
12.07.2023
Dr Reddys Laboratories Q1 PAT seen up 73.7% YoY to Rs 912.4 cr: Nirmal Bang
24.01.2023
Dr Reddy’s Q3 Preview | Sharp drop in net profit likely on slump in US revenues
27.10.2022
Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz